Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin

뉴스 본문을 불러오고 있어요.

Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin | 웨이프 WAPE

Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin

기사 요약

관련 종목

댓글 —